NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Whitlock EP, O'Connor EA, Williams SB, et al. Effectiveness of Weight Management Programs in Children and Adolescents. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008 Sep. (Evidence Reports/Technology Assessments, No. 170.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Effectiveness of Weight Management Programs in Children and Adolescents

Effectiveness of Weight Management Programs in Children and Adolescents.

Show details

Appendix G. Study eligibility criteria

1.

Populations. The following apply to all Key Questions:

a.

Age 2–18. If study substantially overlaps our age range (e.g., 14–65), include article if results for younger participants reported separately. For study of “young adult” or “college-aged”, exclude unless average age is <19 or “college freshmen” is specified.

b.

Either (a) entire sample is ≥overweight or obese (85th percentile for age and sex-specific BMI, or who meet previously accepted criteria for overweight based on ideal body weight) or (b) ≥50% of the sample are overweight or obese AND ≥80% of the sample have one of the following risk factors for overweight or obesity-related medical problems: Children of overweight parents; Hispanic, Black, or American Indian/Alaska Native; children with the following medical conditions: diabetes, metabolic syndrome, hypertension, lipid abnormalities, or other cardiovascular-related disorders.

c.

Exclude trials in which the sample is limited to youth: (1) with eating disorders, (2) pregnant/ post-partum, (3) overweight/obesity secondary to genetic or medical condition, including Polycystic ovarian syndrome, hypothyroid, Cushings, GH deficiency, insulinoma, hypothalamic disorders (e.g. Froehlich's syndrome), Laurence-Moon-Biedl syndrome, Prader-Willi syndrome, weight gain secondary to medications (e.g., antipsychotics), or (4) other idiosyncratic weight-loss issues.

2.

Study Design.

a.

All studies for KQ1, KQ2, KQ4, and KQ5 must have an outcomes assessment at 6 months or later post-baseline. No minimum follow-up is required for serious (i.e., requiring urgent medical care) adverse events, KQ3.

b.

Behavioral interventions: limit to RCT or CCT with minimal intervention or placebo control, with a minimum of 10 subjects per treatment arm

c.

Pharmacological interventions: RCT with placebo pill control, with a minimum of 10 subjects per treatment arm

d.

Surgical interventions: RCT, CCT, systematically selected large case-series, large comparative cohort studies.

3.

Setting. For Behavioral interventions: all KQ except serious (i.e., requiring urgent medical care) adverse effects (KQ3): limit to countries listed as “high” human development on Human Development Index (over .90): Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Hong Kong, Iceland, Ireland, Israel, Italy, Japan, Korea, Luxembourg, Netherlands, New Zealand, Norway, Portugal, Singapore, Slovenia, Spain, Sweden, Switzerland, United Kingdom, United States.

4.

Intervention.

a.

Include behavioral (published ≥1985), pharmacological, complimentary/alternative, surgical, or health care system interventions, singly or combined, designed to promote weight control/loss or weight maintenance, or an important components of weight loss (e.g., physical activity).

b.

Exclude trials in which intervention focuses primary prevention, changes in the build environment, jejunal ileal bypass surgery, mazindol.

Views

  • PubReader
  • Print View
  • Cite this Page

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...